Gilead PepStar deal buys an oral IL 23R peptide for $1.275 billion with no plant attached

The Gilead PepStar deal moves a Chinese oral peptide program into a large US drug company for $1.275 billion in cash. Gilead Sciences said on 22 October 2026 that it signed a definitive agreement to buy the oral IL-23 receptor program of PepStar Therapeutics, led by a candidate called HCXT-2001. The molecule is in Phase 1 testing. No plant, production site or supply contract was part of the announcement, so the money buys a molecule and its rights rather than any capacity.

What Gilead is paying for

Under the terms Gilead set out, as reported by BioPharm International, the company will pay $1.275 billion upfront in cash at closing, subject to customary adjustments. In return it takes worldwide rights to the PepStar program aimed at the IL-23 receptor, with HCXT-2001 as the lead asset. Gilead calls the drug an investigational macrocyclic peptide that patients would swallow, built for a long half-life. Closing is expected in the fourth quarter of 2026, once customary conditions are met. Gilead also told investors the purchase would lower its GAAP and non-GAAP earnings per share by about $0.79 to $0.83 in that quarter. The release describes only the upfront payment, with no milestones or royalties, which sets it apart from many licensing deals where most of the headline value depends on future events.

PepStar is a privately held, clinical stage company based in Shanghai, founded and run by Haibing Guo. Its trial record names the sponsor as Shanghai Peptidstar Therapeutics Limited. Gilead is buying the program, not the company itself. Guo said the sale "marks a major milestone for our company" and that it shows "the strength of our proprietary oral peptide platform." For this site's beat, that split matters. The design know-how that lets a peptide survive the gut is part of the seller's pitch, while the buyer takes one asset forward on its own. Lazard advised Gilead on the money side and Centerview Partners advised PepStar, the release said. Covington and Burling and Mayer Brown acted as legal counsel for Gilead, and Sidley Austin acted for PepStar.

Where HCXT 2001 stands in the clinic

The program is early. A Phase 1 study listed on the ClinicalTrials.gov registry tests two tablet versions, HCXT-2001 tablets and HCXT-2001 tablets (A), after a single administration in healthy adults. The record describes a randomized, sequential design with quadruple masking and an estimated enrollment of 40 people. It names three research sites in New Zealand, in Takapuna, Christchurch and Grafton. The estimated start date was 14 October 2026, and primary completion is estimated for 10 November 2026. The record was first posted on 28 August 2026 and last updated on 13 October 2026. Its stated goals are safety, tolerability, pharmacokinetics and immunogenicity, so the study is built to show how the tablets behave in the body rather than whether they treat disease.

Neither company has disclosed clinical data, and the registered study enrolls healthy volunteers rather than people with inflammatory bowel disease.

Neither company has disclosed clinical data, and the registered study enrolls healthy volunteers rather than people with inflammatory bowel disease. Gilead said safety and efficacy have not been established and that no regulator has approved the drug. The company named inflammatory bowel disease as the main target and mentioned possible use in psoriasis. Chief medical officer Dietmar Berger said Gilead sees potential for the drug "alone or in combination, including with emvistegrast," as a daily oral treatment for people with IBD. Emvistegrast is Gilead's own investigational oral inhibitor of alpha 4 beta 7 integrin. On 19 October 2026 Gilead reported that it met the primary endpoint of a Phase 2 study called SWIFT in ulcerative colitis. Those results have not been peer reviewed, and no combination of the two drugs has been tested.

The oral peptide race it joins

HCXT-2001 is not the first pill in its class. In March 2026 the FDA approved icotrokinra from Johnson and Johnson, sold as Icotyde, an oral peptide that blocks the IL-23 receptor, for moderate to severe plaque psoriasis in adults and in children aged 12 and older, according to the same trade report. Johnson and Johnson is also testing icotrokinra in ulcerative colitis and Crohn's disease. That approval shows regulators have accepted a peptide of this kind in tablet form. It also sets the bar for Gilead, since any later entrant needs a reason to be chosen over a drug already on the market. Gilead has not said how HCXT-2001 differs from icotrokinra beyond calling its own approach potentially differentiated, and no head to head data exist.

For manufacturing, an oral peptide is a different job from an injectable one. A macrocyclic peptide is a chain of amino acids closed into a ring, a shape chosen to resist the gut enzymes that break down ordinary peptides. Tablets also skip the sterile filling lines that pens and vials need, which is where much recent GLP 1 spending has gone, such as the Novo Nordisk fill and finish plant in Clayton, North Carolina. Neither Gilead nor PepStar said where HCXT-2001 is made today, who supplies its active ingredient, or what scale of synthesis later trials would need. Those questions usually come up only once a program moves into larger studies in patients, and Gilead has not given a date for that step.

What the Gilead PepStar deal changes for supply

In the near term, the Gilead PepStar deal moves no capacity. No plant changes hands, no contract maker is named and no build plan was announced. What moves is control of a molecule developed in Shanghai, with worldwide rights, to a company based in California. The supply questions come later: whether Gilead keeps synthesis with partners in China, moves it into its own network, or spreads it across contract makers elsewhere. Any such choice will be made with US policy in view. A reworked BIOSECURE Act was added to the US defence bill for 2026 after failing in 2024, and it limits federal money for firms that use certain biotechnology companies of concern. Nothing in the Gilead release links this purchase to that law.

Scale is the other open point. A single dose study in about 40 healthy adults needs little material, and making a peptide at that size is a very different task from the large batches that a pivotal trial or a launch would require. Our explainer on why one kilo of peptide drug can need thousands of kilos of material shows why scale up drives cost for this class of medicine. Oral delivery adds its own pressure, since a pill must carry enough drug to survive the gut and still reach the blood. Until Gilead says how and where it will make HCXT-2001, the purchase remains a pipeline story with an unanswered manufacturing question attached to it.

Conclusion

The Gilead PepStar deal is a $1.275 billion cash bet on an oral macrocyclic peptide that has only reached Phase 1 testing in healthy adults. It brings no plant and no capacity, and neither company has released clinical data. The facts to watch next are the closing, expected in the fourth quarter of 2026, any first results from the New Zealand study, and where Gilead decides to make the active ingredient.